首页 > 市场调查报告书 > 製药

循环系统

肺动脉高压市场规模、份额和成长分析（按药物类别、类型、给药途径、分销管道和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1896848

肺动脉高压市场规模、份额和成长分析（按药物类别、类型、给药途径、分销管道和地区划分）－2026-2033年产业预测

Pulmonary Arterial Hypertension Market Size, Share, and Growth Analysis, By Drug Class (Endothelin Receptor Antagonists, PDE-5 Inhibitors), By Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球肺动脉高压 (PAH) 市场规模预计在 2024 年达到 82 亿美元，从 2025 年的 86.3 亿美元增长到 2033 年的 130.5 亿美元，在预测期（2026-2033 年）内复合年增长率为 5.3%。

市场分析显示，肺动脉高压 (PAH) 市场的成长主要受以下因素驱动：该疾病盛行率不断上升、政府对孤儿药研发的大量投资以及人口快速老化。 PAH 的特征是由于血管重塑导致肺小动脉阻力增加，据报导其盛行率在每 10 万人中为 0.4% 至 1.4%。此外，全球约有 12.8 亿 30 至 79 岁的人患有高血压，其中大多数生活在中低收入国家。这一日益严重的健康危机与降低高血压盛行率这一全球非传染性疾病控制的关键目标一致，凸显了 PAH 市场对有效治疗方法日益增长的需求。

全球肺动脉高压市场驱动因素

肺动脉高压（PAH）是一种进行性性疾病，会导致肺部动脉血压升高。由于人口老化、肥胖率上升以及诊断技术的进步等因素，全球PAH发生率呈上升趋势。随着越来越多的患者被发现和确诊，这些趋势可能会推动对有效PAH治疗方法的需求不断增长。这些因素共同凸显了开发创新解决方案和治疗方法以应对全球PAH挑战的必要性。

全球肺动脉高压 (PAH) 市场阻碍因素

由于肺动脉高压 (PAH) 的罕见性，全球 PAH 市场面临严峻挑战。与其他慢性疾病相比，PAH 患者数量相对较少，有限的患者群体可能会对 PAH 相关药物的商业性前景产生负面影响，并抑制研发投资。 PAH 的诊断较为复杂，可能需要进行多项检查，例如心臟超音波图和右心导管检查，这使得诊断过程较为繁琐。此外，PAH 的症状，例如疲劳和呼吸困难，通常特异性，并且可能与其他多种疾病有关，这可能导致误诊和延误治疗。

全球肺动脉高压（PAH）市场趋势

全球肺动脉高压 (PAH) 市场正经历着向个人化医疗的重大转变，这主要得益于技术进步和对疾病遗传基础的深入了解。随着越来越多的公司寻求发现能够准确预测疾病进展和治疗反应的生物标记物，这一趋势正推动研发投入的增加。此外，针对特定基因突变的治疗方法也日益受到关注，这些疗法已显着改善了治疗效果和患者预后。这些创新有望推动市场成长，反映出市场对满足 PAH 患者独特需求的个人化治疗方案的需求日益增长。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

United Therapeutics Corporation（United States）
Bayer AG（Germany）
GlaxoSmithKline plc（United Kingdom）
Gilead Sciences, Inc.（United States）
Novartis International AG（Switzerland）
Pfizer Inc.（United States）
Merck & Co., Inc.（United States）
Bristol-Myers Squibb Company（United States）
Teva Pharmaceutical Industries Ltd.（Israel）
Viatris Inc.（United States）
Sun Pharmaceutical Industries Ltd.（India）
Alembic Pharmaceuticals Ltd.（India）
Aerami Therapeutics Holdings Inc.（United States）
Asklepion Pharmaceuticals LLC（United States）
Keros Therapeutics（United States）
Liquidia Corporation（United States）
Ferrer（Spain）
Gossamer Bio（United States）

结论与建议

简介目录

Product Code: SQMIG35H2222

Global Pulmonary Arterial Hypertension Market size was valued at USD 8.2 Billion in 2024 and is poised to grow from USD 8.63 Billion in 2025 to USD 13.05 Billion by 2033, growing at a CAGR of 5.3% during the forecast period (2026-2033).

Market insights indicate that the growth of the pulmonary arterial hypertension (PAH) sector is significantly propelled by the increasing incidence of the condition, substantial government investments in orphan drug development, and a burgeoning elderly population. PAH is characterized by elevated resistance in pulmonary arterioles due to vascular remodeling, with a reported prevalence ranging from 0.4% to 1.4% per 100,000 individuals. Furthermore, a considerable global population of approximately 1.28 billion individuals aged 30-79 suffers from hypertension, predominantly found in low- and middle-income nations. This growing health crisis aligns with international objectives targeting a reduction in hypertension prevalence as a key component of the response to non-communicable diseases, underscoring the increasing demand for effective treatments within the PAH market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pulmonary Arterial Hypertension market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pulmonary Arterial Hypertension Market Segments Analysis

Global Pulmonary Arterial Hypertension Market is segmented by Drug Class, Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs and SGC Stimulators. Based on Type, the market is segmented into Branded and Generics. Based on Route of Administration, the market is segmented into Oral, Intravenous/ subcutaneous and Inhalational. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pulmonary Arterial Hypertension Market

Pulmonary arterial hypertension (PAH) is a rare and progressive disease marked by heightened blood pressure within the arteries that transport blood to the lungs. The global incidence of PAH is on the rise, driven by factors such as an aging population, increasing obesity rates, and advancements in diagnostic capabilities. These trends are likely to foster a growing demand for effective PAH treatments, as more individuals are identified and diagnosed with this condition. The combination of these elements underscores the necessity for innovative solutions and therapies to address the challenges posed by PAH on a worldwide scale.

Restraints in the Global Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension (PAH) market faces significant challenges due to the rarity of the disease, resulting in a relatively small patient population when compared to other chronic conditions. This limited patient base can adversely affect the commercial prospects of PAH-related medications, deterring investment in their development. Diagnosing PAH is complex and requires multiple tests, such as echocardiograms and right heart catheterizations, which can complicate the process. Furthermore, the symptoms of PAH, including fatigue and shortness of breath, are often non-specific and may be linked to various other illnesses, which can lead to misdiagnosis or delays in appropriate treatment.

Market Trends of the Global Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension (PAH) market is witnessing a significant shift towards personalized medicine, driven by technological advancements and a deeper understanding of the genetic underpinnings of the disease. This trend is fostering increased investments in research and development as companies strive to discover biomarkers that enable precise predictions of disease progression and treatment responses. Additionally, the focus on therapies targeting specific genetic mutations is gaining momentum, enhancing treatment efficacy and patient outcomes. With these innovations, the market is anticipated to expand, reflecting a growing demand for tailored therapeutic approaches that meet the unique needs of PAH patients.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Pulmonary Arterial Hypertension Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Endothelin Receptor Antagonists (ERAs)
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
SGC Stimulators

Global Pulmonary Arterial Hypertension Market Size by Type & CAGR (2026-2033)

Market Overview
Branded
Generics

Global Pulmonary Arterial Hypertension Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Intravenous/ subcutaneous
Inhalational

Global Pulmonary Arterial Hypertension Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospitals
Retail Pharmacies
Online Pharmacies

Global Pulmonary Arterial Hypertension Market Size & CAGR (2026-2033)

North America (Drug Class, Type, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Drug Class, Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Type, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

United Therapeutics Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alembic Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aerami Therapeutics Holdings Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Asklepion Pharmaceuticals LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Keros Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Liquidia Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferrer (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gossamer Bio (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments